Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 4/20 | 0.41 |
| ▸ | GPR6 | P46095 | 3/20 | 0.39 |
| ▸ | RHOC | P08134 | 4/20 | 0.39 |
| ▸ | RHOA | P61586 | 4/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
| ▸ | UBE2M | P61081 | 1/20 | 0.38 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.38 |
| ▸ | NPY2R | P49146 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2693705 | 1.00 | MCHR1 (0.41) | MCHR1GPR6RHOCRHOAIRAK4 | |
| SCHEMBL6372235 | 0.94 | GPR6 (0.39) | MCHR1GPR6RHOCRHOAIRAK4 | |
| SCHEMBL1258330 | 0.94 | GPR6 (0.39) | MCHR1GPR6RHOCRHOAIRAK4 | |
| SCHEMBL6372228 | 0.92 | MCHR1 (0.41) | MCHR1GPR6RHOCRHOAIRAK4 | |
| SCHEMBL6373771 | 0.92 | GPR6 (0.39) | MCHR1GPR6RHOCRHOAIRAK4 | |
| SCHEMBL6373742 | 0.92 | GPR6 (0.41) | GPR6RHOCRHOAMAPTALDH1A1 | |
| SCHEMBL1257296 | 0.92 | GPR6 (0.41) | GPR6RHOCRHOAMAPTALDH1A1 | |
| SCHEMBL1255964 | 0.91 | GPR6 (0.40) | GPR6RHOCRHOAMAPT | |
| SCHEMBL1257471 | 0.91 | GPR6 (0.40) | GPR6RHOCRHOAMAPT | |
| SCHEMBL6468623 | 0.91 | GPR6 (0.40) | GPR6RHOCRHOAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140364420-A1 | SUBSTITUTED PIPERAZINYL-PYRROLIDINE COMPOUNDS USEFUL AS CHEMOKINE RECEPTOR ANTAGONISTS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-12-11 | — | — | US | disclosed |
| US-8168788-B2 | Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-20060172994-A1 | Compounds useful as chemokine receptor antagonists | MILLENNIUM PHARMACEUTICALS, INC. | 2006-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060172994-A1 | Compounds useful as chemokine receptor antagonists | ACKR3, CCR5, CXCR2 | MCHR1 443/4885GPR6 111/4885RHOC 1650/4885 |
| US-20140364420-A1 | SUBSTITUTED PIPERAZINYL-PYRROLIDINE COMPOUNDS USEFUL AS CHEMOKINE RECEPTOR ANTAGONISTS | ACKR3, CCR5, CCR2 | MCHR1 523/4885GPR6 163/4885RHOC 1535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.